Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML2653

Sigma-Aldrich

Sorafenib

≥98% (HPLC), powder, kinase inhibitor

Sinonimo/i:

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, BAY 43-9006, BAY43-9006, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H16ClF3N4O3
Numero CAS:
284461-73-0
Peso molecolare:
464.82
Numero MDL:
MFCD06411450
Codice UNSPSC:
12352200
NACRES:
NA.77

Nome del prodotto

Sorafenib, ≥98% (HPLC)

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Stringa SMILE

FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
MLDQJTXFUGDVEO-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Sorafenib (BAY 43-9006) is an orally active kinase inhibitor that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-ß), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Pittogrammi

Health hazardEnvironment
GHS08,GHS09

Avvertenze

Danger

Indicazioni di pericolo

H360FD,H362,H372,H410

Classi di pericolo

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

Codice della classe di stoccaggio

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

2,4,6-Tris(dimethylamino)-1,3,5-triazine 96%

Sigma-Aldrich

549835

2,4,6-Tris(dimethylamino)-1,3,5-triazine

Safranal ≥90%, stabilized

Sigma-Aldrich

W338907

Safranal

DL-Buthionine-(S,R)-sulfoximine

Sigma-Aldrich

B2640

DL-Buthionine-(S,R)-sulfoximine

Midostaurin hydrate ≥98% (HPLC), solid

Sigma-Aldrich

M1323

Midostaurin hydrate

Thioridazine hydrochloride ≥99%

Sigma-Aldrich

T9025

Thioridazine hydrochloride

FIN56 ≥98% (HPLC)

Sigma-Aldrich

SML1740

FIN56

Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder

Sigma-Aldrich

V2264

Vinorelbine ditartrate salt hydrate

Paul T C Wan et al.
Cell, 116(6), 855-867 (2004-03-24)
Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal
Shengnan Liu et al.
Cancer letters, 453, 74-83 (2019-04-01)
Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after
Xudong Gao et al.
OncoTargets and therapy, 12, 1629-1640 (2019-03-19)
Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect
Jeong-Ju Yoo et al.
International journal of molecular sciences, 20(6) (2019-03-17)
This study aimed to examine whether inhibition of hexokinase (HK)-II activity enhances the efficacy of sorafenib in in-vivo models of hepatocellular carcinoma (HCC), and to evaluate the prognostic implication of HK-II expression in patients with HCC. We used 3-bromopyruvate (3-BP)
Mater H Mahnashi et al.
Pharmaceuticals (Basel, Switzerland), 15(2) (2022-02-27)
Over the past few decades, the development of broad-spectrum anticancer agents with anti-angiogenic activity has witnessed considerable progress. In this study, a new series of pyrazolo[3,4-d]pyrimidines based on a phenylfuroxan scaffold were designed, synthesized, and evaluated, in terms of their
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.